Linagliptin Sandoz (Linagliptin)

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus. It helps lower blood glucose when combined with diet and exercise.

• Type 2 diabetes mellitus: improves glycemic control as part of a comprehensive treatment plan.
• Adjunct to metformin: provides additional HbA1c reduction when metformin alone is insufficient.
• Combination therapy: can be co‑administered with insulin or other oral agents to achieve target glucose levels.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this breakdown, circulating levels of GLP‑1 and GIP rise, leading to glucose‑dependent enhancement of insulin secretion from pancreatic β‑cells and suppression of glucagon release from α‑cells, thereby lowering post‑prandial and fasting blood glucose.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nasal passages and throat.
• Headache: transient, mild to moderate intensity.
• Upper respiratory tract infection: symptoms of cough, sore throat, or congestion.
• Dizziness: occasional light‑headedness, especially on standing.
• Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention.
• Severe allergic reactions: anaphylaxis, angioedema, or rash requiring discontinuation.
• Hepatic injury: elevated liver enzymes or hepatitis signs.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Linagliptin, clinicians should consider several safety factors.

• Renal impairment: dose adjustment is generally not required, but renal function should be monitored.
• Hepatic impairment: use with caution in patients with moderate to severe liver disease.
• Cardiovascular disease: no specific contraindication, but monitor for any new symptoms.
• Hypoglycemia risk: increased when combined with insulin or sulfonylureas; adjust concomitant therapy accordingly.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Insulin or sulfonylureas: may cause severe hypoglycemia; dose adjustments are necessary.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase linagliptin exposure and risk of adverse effects.
• Rifampin: may reduce linagliptin efficacy by inducing metabolism.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor for dehydration, especially in elderly patients.

• ACE inhibitors: observe blood pressure and renal function.
• Warfarin: periodic INR monitoring is advised due to potential interaction.